Global Erythropoietin Stimulating Agent Market Key Trends & Industry Forecast 2015-2023
GlobalErythropoietin stimulating agent market are driven by increasing number of patients suffering from anemia, anemia induced due to cancer, end stage renal disease (ESRD) and HIV treatment. In June 1989,Epoetin alfa was the first drug for EPO, manufactured by Amgen Inc. U.S FDA approved itunder the trade name "Epogen".The global market for erythropoietin drugs are expected to grow in near future as increased cases of cancer and renal problem haveregistered. With the expiration of Amgen's patent for Epogen, it has...
View full press release